WCG Wealth Advisors LLC Purchases New Stake in Johnson & Johnson $JNJ

WCG Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 12,965 shares of the company’s stock, valued at approximately $1,980,000.

Other hedge funds also recently modified their holdings of the company. AMJ Financial Wealth Management lifted its holdings in Johnson & Johnson by 492.8% in the second quarter. AMJ Financial Wealth Management now owns 6,556 shares of the company’s stock valued at $130,000 after buying an additional 5,450 shares during the period. Wellspring Financial Advisors LLC grew its holdings in Johnson & Johnson by 1.8% during the 2nd quarter. Wellspring Financial Advisors LLC now owns 15,617 shares of the company’s stock worth $2,385,000 after acquiring an additional 283 shares during the period. Blueshift Asset Management LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $315,000. Westerkirk Capital Inc. acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $4,168,000. Finally, NBW Capital LLC boosted its position in shares of Johnson & Johnson by 11.5% in the 2nd quarter. NBW Capital LLC now owns 1,422 shares of the company’s stock worth $217,000 after purchasing an additional 147 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $205.38 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a market cap of $494.82 billion, a price-to-earnings ratio of 19.82, a PEG ratio of 2.19 and a beta of 0.36. The business has a 50 day simple moving average of $192.54 and a 200 day simple moving average of $174.50. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $207.81.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Scotiabank started coverage on Johnson & Johnson in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price objective for the company. Citigroup boosted their target price on Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, October 15th. Argus set a $210.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Finally, Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Four research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $202.10.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.